The ITGB6 gene: its role in experimental and clinical biology

Amelia Meecham; John F Marshall

doi:10.1016/j.gene.2019.100023

The ITGB6 gene: its role in experimental and clinical biology

Gene X. 2019 Nov 6:5:100023. doi: 10.1016/j.gene.2019.100023. eCollection 2020 Dec.

Authors

Amelia Meecham¹, John F Marshall¹

Affiliation

¹ Centre for Tumour Biology, Barts Cancer Institute, Cancer Research UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK.

Abstract

Integrin αvβ6 is a membrane-spanning heterodimeric glycoprotein involved in wound healing and the pathogenesis of diseases including fibrosis and cancer. Therefore, it is of great clinical interest for us to understand the molecular mechanisms of its biology. As the limiting binding partner in the heterodimer, the β6 subunit controls αvβ6 expression and availability. Here we describe our understanding of the ITGB6 gene encoding the β6 subunit, including its structure, transcriptional and post-transcriptional regulation, the biological effects observed in ITGB6 deficient mice and clinical cases of ITGB6 mutations.

Keywords: CREB, cAMP response element; Cancer; Fibrosis; HAT, histone acetyltransferase; HDAC, Histone deacetylase; Integrin; LAP, Latency Associated Peptide; OSCC, oral squamous cell carcinoma cells; STAT3, signal transducer and activator transcription 3; TGFβ1, Transforming growth factor β1; UTR, Untranslated region.

Publication types

Review